Document NGZanQ77MxBVYLLDJrrJEO0ZQ

ORIGINAL December 29, 2009 or. r ' r i u -uiL n o n r r d n ^*4 W J W LW L J J if J 33 DuPont Haskell Global Centers for Health and Environmental Sciences 1090 Elkton Road, P.O. Box 50 Newark, DE 19714-0050 8 E H Q - 12 0 9-16478J 891000000891 Via Federal Express Document Processing Center (Mail Code 7407M) Room 6428 Attention: 8(e) Coordinator Office of Pollution Prevention and Toxics U.S. Environmental Protection Agency, ICC Building 1201 Constitution Ave., NW Washington, DC 20004 89100000091 891 00000091 Dear 8(e) Coordinator: 8EHQ-06-16436/8EHQ-06-16478 This letter is to inform you of the results o f a 90-day oral toxicity study in mice with the above referenced test substance. This test substance is subject to a Consent Order, PMN P-08-509. Four groups o f young adult male and female CrhCDl mice (10/sex/group) were dosed by oral gavage for at least 90 days. Mice were dosed with the test substance in deionized water at doses o f 0 (control), 0.1, 0.5, or 5 mg/kg/day of the test substance. The control mice were dosed with deionized water at the same dose volume as the high dose group. In the animals designated for subchronic toxicity evaluation, body weights, food consumption, and detailed clinical observations were evaluated weekly and acute clinical observations were evaluated daily. All mice received ophthalmology examinations prior to study start and all subchronic toxicity mice were examined near the end o f the dosing period. Neurobehavioral evaluations (abbreviated functional observational battery [FOB] and motor activity) were evaluated in all subchronic toxicity mice prior to study start (including spares) and near the end o f dosing. Clinical pathology endpoints (hematology, clinical chemistry, coagulation parameters) were evaluated at the end of the exposure period. After 96 (males) or 97 (females) days of dosing, the surviving mice were sacrificed and given a gross and microscopic pathological examination. No test substance-related deaths occurred. No neurobehavioral, clinical or ophthalmological observations were attributed to exposure to the test substance. No deaths, clinical or ophthalmological observations, or neurobehavioral effects were attributed to test substance exposure. Body weight and nutritional parameters in the 5 mg/kg/day male group were higher than in controls during the exposure period; the body weight increases were attributed mainly to increased liver weight. No test substance-related effects on body weight, body weight gain, food consumption, or food efficiency were observed in males in lower dose groups or in females in any dose group. Preliminary clinical and anatomic pathology data are available. These data indicate there were no adverse, treatment-related changes in hematology, coagulation, or urinalysis parameters attributed to exposure to the test . substance. Total bile acids and liver enzymes (alanine aminotransferase, alkaline phosphatase, sorbitol dehydrogenase, and aspartate aminotransferase (males only) were increased in both sexes at 5 mg/kg/day and were associated with increased liver weights and liver microscopic pathology: hypertrophy, focal necrosis, and increased binucleate hepatocytes (males and females), and increased mitoses, apoptosis, and Kupffer cell pigment (males only). Liver hypertrophy was also observed in males at 0.5 mg/kg/day. Increased albumin (both sexes) and total protein (males only) were observed at 5 mg/kg/day. Effects were generally more severe in males than in females. Other statistically significant clinical pathology differences included increased platelets in 0.5 and 5 mg/kg/day males, increased monocytes in 0.1 mg/kg/day females, reduced cholesterol in 5 mg/kg/day males, increased albumin and total protein (males only) in 5 mg/kg/day males and females, reduced bilirubin in 5 mg/kg/day females, increased chloride in 5 mg/kg/day males, reduced potassium in 5 mg/kg/day males and females. Other statistically r CONTAINS NO C8I significant anatomic pathology differences of uncertain relationship to treatment included slightly increased adrenal weights with adrenal cortical hypertrophy, increased kidney weight with minimal tubular epithelial hypertrophy in 5 mg/kg/day males, and reduced spleen weight with no corroborative pathological changes. This information is submitted in accordance with current guidance issued by EPA indicating EPA's interpretation of Section 8(e) of the Toxic Substances Control Act or, where it is not clear that reporting criteria have been met, it is submitted as a precautionary measure and because it is information in which EPA may have an interest. Sincerely, A. Michael Kaplan, Ph.D. Director - Regulatory Affairs AMK/SAM: cip (302) 366-5260 RECIPIENT; PEEL HERE .USAirbill Express FadEx Tracking Number 1 From This portioncan beremovedforReeipisnisreconte. ^7 ~~( '"7Pete j X " 3 FedEx Tracking Number f i 7 D ^ 7 S . S Mi fl?[n?55fl4i47Li Sender's Name f ' f i ( c L u d ' j d a / P - f a k Phone 3 ^ 0 )' Company DUPQN f / l P X k / S T i Q9Q ELKTO.M RD cityNEWARK 2 Your Internal B illin g Reference S t a t e ____ h ZIP 1 OeptyFloor/Sufte/Room 3 To Recipient's,; Name (./r e( H Phone / y S f Comparu j%!icid<s Address' t(X \if 3oi O We cannot deliver to P.O. boxed'or PO. ZIP HOLD Weekday HOLD Saturday n t t<ttl/ve L X fl'O. bPreilnotwF.eNdOExTlaocvaatiiloanblaedtdorress I 1, APrvinatilFaebdleExOlNocLaYtitoonrFaedddErexsPsrbioerliotywOvernight FedEx First Overnight I-- I end FedEx 2Dayto selectlocations. Deffc/Floor/Suite/floom Address Print FedEx location address here if HOLD option Is selected. C ity/^ V J CStated ' zip ( p o y El'S W `-` 4a Express Package Service Tomoataati, FedEx Priority Overnight Next business morning* Friday, shipments will be delivered on Monday unless SATURDAY Deliveryis selected i- t IEx Standard Overnight K l Nextbusi.n...e..s..s..a..fIt*e...r.n...o...o...n** Saturday Delivery NOT available rFeeudcEx^2uDay Secondbusmessday*Thursday sWprrwrtejNittbedelivBfed on Monday unless SATURDAY Delivery is selected .-- i FedEx Express Saver Third business day* 1-- SaturdayDeliveryNOT available 4b Express Freight Service FedEx 1Day Freight Next business aay.** Fnday shipments will K r i S ndaV" nl" !SSATM " DAY ** To most locations. IDay FreightBookingNa I Packages upto 150ibs. FedEx First Overnight Earliest next business morning delivery to select locations* Saturday Delivery NOT available, Packages ovar ISOIbs. Second business day^Thursday shipmentswill be delivered on Monday unless SATURDAY Deliveryis selected 5 Packaging * Declared value limit$500. n FedEx 1-- 1 E m / a ln n fi* ^ F l FedEx Pak* -- Includes FedEx Small Pak, FedEx Large Pak, and FedEx Sturdy Pak. I I FedEx 3DaV Freight I____I Third business osy.** SSaattuurerdayDeliveryNOT available I I FedEx B ox Q FedEx Tube [ ] Othe 6 Sp ecial Handling and D elivery Signature Options f l SATURDAY Delivery 1-- I NOT availablefor FedEx Standard Overnight FedEx First Overnight FedEx Express Saver, or FedEx 3Day Freight n No Signature Required Package may be leftwithout -- obtaining a signature for delivery -- Direct Signature Someone atrecipient'saddress -- 1 maysignfordelrvery Fee applies. Does this shipment contain dangerous goods? I------------------------- One box must be checked.------------------------1 Indirect Signature lino one is available at recipients address, someone ata neighbonng address maysign for delivery For residential deliveries only f i applies. No 1 ! As per attached 1 1 STnppeT'sDeclaration 1-- 1 Shipper'ss Declaration I--I-- II nnoottrereoquuirireedd Dangerous goods (including dry ice) cannot be shipped mFedEx packaging orplaced in a FedEx Express Orop 8ox ! 1 D P /IC B I-- ' DDrryyiiccee,,99,,lUN 1845 - I I Cargo A ircraft Only 7 Payment Biiito: EnterFedExA cci No. orCredit CardNo. below 0 Recipient Q Third Party Q Credit Card Obtain Recip. >-- A c c i No. I____l Q Cash/Check L 8709 7258 4476 ^Ourliabilityis limitedto $100 unless you declare a highervalue. See the current FedEx Service Guide for details Rev. Date 2/0W>art*t5e279l99`V-2008 FedExPRlNTED IN U S A*SRS